The tweet was deleted by the author.
But we saved everything 🙂.
CVRx has announced the publication of a new case study aimed at healthcare providers, focusing on ambulatory hemodynamic changes and strategies for diuretic de-escalation in patients with heart failure with reduced ejection fraction (HFrEF).
The study is positioned as an informative resource for clinicians exploring advanced heart failure management and could contribute to evolving best practices in patient care. No details regarding patient outcomes or next steps were disclosed in the announcement.
View post on X Loading...
CVRx previously partnered with Baylor Scott and White Medical Center in Temple, Texas, for their first Barostim implant procedure. The company also collaborated with Florida Medical Clinic Orlando Health to introduce the first Barostim implant at that location, expanding heart failure treatment options in the region. Both initiatives reflect CVRx’s ongoing efforts to support advanced therapies in heart failure management.